TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year’s annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Anthony
Novel Particle Therapy Whitepaper
Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.
TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment
Rob Hill Promoted to CEO of TAE Life Sciences as Company Pursues Global Clinical Trials
Preliminary Results Show TAE Life Sciences’ TC440 Boron-Containing Drug Holds Promise for Revolutionizing Cancer Treatment Strategies
Preliminary Results Show TAE Life Sciences’ Novel Boron-Containing Drug Holds Promise for Revolutionizing Boron Neutron Capture Therapy
TAE Life Sciences, a pioneering company in the field of cancer treatment, today announces the results from early testing of its TC440 boron-containing dipeptide compound for Boron Neutron Capture Therapy (BNCT).
Leading Cancer Center in Poland Announce Plans for a New State-of-the-Art BNCT Facility
TAE Life Sciences, a global leader in advanced biological-targeted radiation therapy, and creator of next-genera on boron neutron capture therapy (BNCT) systems, and the Franciszek Łukaszczyk Oncology Center (FLOC)
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
TLS and Avita Biomedical Announce Strategic Partnership
Have questions about BNCT? Get answers on our new BNCT Forum